Table 3.

Proportional Hazards Regression Analysis of Patients Surviving More than 3 Years

	Cohort 1 (AMI patients) surviving >3 years		Cohort 2 (CAD only) patients surviving > 3 years
Variable	HR (95% CI)	P	HR (95% CI)	P
Beta blockers	0.71 (0.60, 0.85)	0.001	0.85 (0.80, 0.96)	0.006
ACEI/ARB	0.79 (0.66, 0.94)	0.009	0.79 (0.71, 0.87)	0.001
ADP-antagonist	1.06 (0.81, 1.38)	0.689	1.30 (1.08, 1.58)	0.007
Statin	0.54 (0.45, 0.65)	0.001	0.67 (0.60, 0.74)	0.001
CVD-TIA	1.32 (1.12, 1.56)	0.001	1.31 (1.20, 1.43)	0.001
Chronic kidney disease	1.75 (1.49, 2.06)	0.001	1.85 (1.69, 2.03)	0.001
Diabetes mellitus	1.32 (1.11, 1.57)	0.002	1.26 (1.16, 1.38)	0.001
Peripheral vascular disease	0.99 (0.84, 1.17)	0.932	1.04 (0.95, 1.14)	0.405
Atrial fibrillation	1.28 (1.08, 1.52)	0.004	1.42 (1.29, 1.56)	0.001
Heart failure	1.21 (1.01, 1.94)	0.035	1.32 (1.21, 1.45)	0.001
Hypertension	0.42 (0.06, 3.01)	0.384	1.24 (0.79, 1.93)	0.353
Female	0.83 (0.71, 0.97)	0.018	0.77 (0.71, 0.84)	0.001
Age	1.06 (1.05, 1.07)	0.001	1.07 (1.07, 1.07)	0.001
Black	1.12 (0.95, 1.32)	0.183	0.95 (0.86, 1.04)	0.248

ACEI/ARB, angiotensin converting enzyme inhibitors/angiotensin receptor blockers; ADP, adenosine diphosphate; AMI, acute myocardial infarction; CVD-TIA, cardiovascular disease-transient ischemic attack.